We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
Read MoreHide Full Article
Krystal Biotech (KRYS - Free Report) announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.
The phase I/II KYANITE-1 study is evaluating the safety, tolerability and tumor response (measured using RECIST v1.1 criteria) of inhaled KB707 as a monotherapy in 37 patients with malignant lesions in the lung. Out of the total enrolled patient population, 17 were diagnosed with advanced non-small cell lung cancer (NSCLC). Two doses of KB707 (108 PFU or 109 PFU) were evaluated during the dose-escalation phase of the KYANITE-1 study, following which 109 PFU was selected for dose expansion.
Results showed that patients treated with inhaled KB707 demonstrated early evidence of monotherapy activity with the most therapeutic benefit observed in advanced NSCLC patients, who have progressed after standard-of-care treatments.
In the past three months, shares of Krystal Biotech have lost 14.9% compared with the industry’s 13.3% decline.
Image Source: Zacks Investment Research
More on KRYS’Development of KB707 for Lung Cancer
Out of the 17 NSCLC patients treated with inhaled KB707 in Krystal Biotech’s KYANITE-1 study, 11 were evaluable for response with at least one radiographic scan and RECIST v1.1 evaluation as of data cut-off on Dec. 6, 2024.
The analyzed patients had undergone extensive treatment, with a median of four prior therapy lines, including at least one immunotherapy. In this NSCLC cohort, an overall response rate (ORR) of 27% was observed, with three partial responses. The disease control rate (DCR) reached 73%, with seven out of 11 patients continuing treatment. Treatment durations ranged from 10.3 to 33.3 weeks as of the data cut-off.
Additionally, Krystal Biotech reported that treatment with inhaled KB707 showed promising results outside the lungs, with notable responses in lung lesions. Among the 11 evaluable NSCLC patients, the ORR in target lung lesions specifically was 36%, including three partial responses and one complete response, while DCR was 82%. Despite being early, management believes that the observed monotherapy activity with inhaled KB707 supports the potential of KRYS’ HSV-1 platform to safely and repeatedly deliver functional genetic material to the lung and impact the course of the disease.
Encouraged by positive initial monotherapy results, Krystal Biotech has updated the KYANITE-1 protocol to include two new cohorts studying inhaled KB707 in combination with anti-PD-1 therapy alone or with chemotherapy for advanced NSCLC. Patient enrollment in these combination cohorts has not yet begun. The company expects to disclose detailed and updated results of KYANITE-1 at future medical conferences.
KB707 is also being developed as an intratumoral injection, which is being developed in a phase I/II OPAL-1 study to pre-treated patients with locally advanced or metastatic solid tumors. A data readout from this study is expected soon.
In the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past three months, shares of Castle Biosciences have lost 15.7%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. In the past three months, CTMX stock has lost 10.9%.
CytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past three months, Spero’s shares have lost 25.2%.
SPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
Krystal Biotech (KRYS - Free Report) announced encouraging initial clinical data from an early to mid-stage study of its investigational immunotherapy candidate, KB707, to treat patients with solid tumors of the lung.
The phase I/II KYANITE-1 study is evaluating the safety, tolerability and tumor response (measured using RECIST v1.1 criteria) of inhaled KB707 as a monotherapy in 37 patients with malignant lesions in the lung. Out of the total enrolled patient population, 17 were diagnosed with advanced non-small cell lung cancer (NSCLC). Two doses of KB707 (108 PFU or 109 PFU) were evaluated during the dose-escalation phase of the KYANITE-1 study, following which 109 PFU was selected for dose expansion.
Results showed that patients treated with inhaled KB707 demonstrated early evidence of monotherapy activity with the most therapeutic benefit observed in advanced NSCLC patients, who have progressed after standard-of-care treatments.
In the past three months, shares of Krystal Biotech have lost 14.9% compared with the industry’s 13.3% decline.
Image Source: Zacks Investment Research
More on KRYS’Development of KB707 for Lung Cancer
Out of the 17 NSCLC patients treated with inhaled KB707 in Krystal Biotech’s KYANITE-1 study, 11 were evaluable for response with at least one radiographic scan and RECIST v1.1 evaluation as of data cut-off on Dec. 6, 2024.
The analyzed patients had undergone extensive treatment, with a median of four prior therapy lines, including at least one immunotherapy. In this NSCLC cohort, an overall response rate (ORR) of 27% was observed, with three partial responses. The disease control rate (DCR) reached 73%, with seven out of 11 patients continuing treatment. Treatment durations ranged from 10.3 to 33.3 weeks as of the data cut-off.
Additionally, Krystal Biotech reported that treatment with inhaled KB707 showed promising results outside the lungs, with notable responses in lung lesions. Among the 11 evaluable NSCLC patients, the ORR in target lung lesions specifically was 36%, including three partial responses and one complete response, while DCR was 82%. Despite being early, management believes that the observed monotherapy activity with inhaled KB707 supports the potential of KRYS’ HSV-1 platform to safely and repeatedly deliver functional genetic material to the lung and impact the course of the disease.
Encouraged by positive initial monotherapy results, Krystal Biotech has updated the KYANITE-1 protocol to include two new cohorts studying inhaled KB707 in combination with anti-PD-1 therapy alone or with chemotherapy for advanced NSCLC. Patient enrollment in these combination cohorts has not yet begun. The company expects to disclose detailed and updated results of KYANITE-1 at future medical conferences.
KB707 is also being developed as an intratumoral injection, which is being developed in a phase I/II OPAL-1 study to pre-treated patients with locally advanced or metastatic solid tumors. A data readout from this study is expected soon.
Krystal Biotech, Inc. Price and Consensus
Krystal Biotech, Inc. price-consensus-chart | Krystal Biotech, Inc. Quote
KRYS’ Zacks Rank & Stocks to Consider
Krystal Biotech currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the sector are Castle Biosciences (CSTL - Free Report) , CytomX Therapeutics (CTMX - Free Report) and Spero Therapeutics (SPRO - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, 2024 estimates for Castle Biosciences have improved from a loss of 59 cents per share to earnings of 34 cents. During the same timeframe, loss per share estimates for 2025 have narrowed from $2.15 to $1.84. In the past three months, shares of Castle Biosciences have lost 15.7%.
CSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.
In the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 29 cents to 5 cents. Estimates for 2025 loss per share have narrowed from 56 cents to 35 cents during the same timeframe. In the past three months, CTMX stock has lost 10.9%.
CytomX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.
In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.29. Estimates for 2025 loss per share have narrowed from $1.54 to 79 cents during the same timeframe. In the past three months, Spero’s shares have lost 25.2%.
SPRO’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 94.42%.